Compare BioNano Genomics Inc (BNGO) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs McDonald's Corp — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while McDonald's Corp trades at $273.5 (market cap $194.00B). The key difference: McDonald's Corp is far larger — about 14202× BioNano Genomics Inc's market cap, and McDonald's Corp pays a 2.71% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MCD | |
|---|---|---|
Market Cap | $13.66M | $194.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $341.06 |
52-Week Low | $1.06 | $262.80 |
Enterprise Value | $16.26M | $247.77B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
McDonald's (MCD) trades at $273.72, down 0.28% on the day, with a neutral technical signal and strong fundamentals including a 31.72% net margin and consistent earnings beats. The company recently unveiled its 'McDonald's NEXT' growth strategy focusing on automation and menu innovation to drive future performance. Revenue growth remains steady, with 2025 revenue at $26.89 billion.
Outlook is positive with a consensus price target of $322.45 offering 17.8% upside, supported by 60% analyst buy ratings. Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock presents a value opportunity with stable dividends and strategic initiatives aimed at enhancing competitiveness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
